Literature DB >> 19233853

Structural determinants of drugs acting on the Nav1.8 channel.

Liam E Browne1, Frank E Blaney, Shahnaz P Yusaf, Jeff J Clare, Dennis Wray.   

Abstract

The aim of this work is to study the role of pore residues on drug binding in the Na(V)1.8 channel. Alanine mutations were made in the S6 segments, chosen on the basis of their roles in other Na(V) subtypes; whole cell patch clamp recordings were made from mammalian ND7/23 cells. Mutations of some residues caused shifts in voltage dependence of activation and inactivation, and gave faster time course of inactivation, indicating that the residues mutated play important roles in both activation and inactivation in the Na(V)1.8 channel. The resting and inactivated state affinities of tetracaine for the channel were reduced by mutations I381A, F1710A, and Y1717A (for the latter only inactivated state affinity was measured), and by mutation F1710A for the Na(V)1.8-selective compound A-803467, showing the involvement of these residues for each compound, respectively. For both compounds, mutation L1410A caused the unexpected appearance of a complete resting block even at extremely low concentrations. Resting block of native channels by compound A-803467 could be partially removed ("disinhibition") by repetitive stimulation or by a test pulse after recovery from inactivation; the magnitude of the latter effect was increased for all the mutants studied. Tetracaine did not show this effect for native channels, but disinhibition was seen particularly for mutants L1410A and F1710A. The data suggest differing, but partially overlapping, areas of binding of A-803467 and tetracaine. Docking of the ligands into a three-dimensional model of the Na(V)1.8 channel gave interesting insight as to how the ligands may interact with pore residues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233853      PMCID: PMC2667739          DOI: 10.1074/jbc.M807569200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels.

Authors:  W A Catterall
Journal:  Neuron       Date:  2000-04       Impact factor: 17.173

2.  Nomenclature of voltage-gated sodium channels.

Authors:  A L Goldin; R L Barchi; J H Caldwell; F Hofmann; J R Howe; J C Hunter; R G Kallen; G Mandel; M H Meisler; Y B Netter; M Noda; M M Tamkun; S G Waxman; J N Wood; W A Catterall
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

3.  Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit.

Authors:  V Yarov-Yarovoy; J Brown; E M Sharp; J J Clare; T Scheuer; W A Catterall
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

Review 4.  Molecular mechanisms of gating and drug block of sodium channels.

Authors:  William A Catterall
Journal:  Novartis Found Symp       Date:  2002

5.  Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels.

Authors:  G Liu; V Yarov-Yarovoy; M Nobbs; J J Clare; T Scheuer; W A Catterall
Journal:  Neuropharmacology       Date:  2003-03       Impact factor: 5.250

6.  Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel alpha subunit in voltage-dependent gating and drug block.

Authors:  Vladimir Yarov-Yarovoy; Jancy C McPhee; Diane Idsvoog; Caroline Pate; Todd Scheuer; William A Catterall
Journal:  J Biol Chem       Date:  2002-07-18       Impact factor: 5.157

7.  Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8.

Authors:  Josephine Lai; Michael S Gold; Chang Sook Kim; Di Bian; Michael H Ossipov; John C Hunter; Frank Porreca
Journal:  Pain       Date:  2002-01       Impact factor: 6.961

8.  A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain.

Authors:  B J Kerr; V Souslova; S B McMahon; J N Wood
Journal:  Neuroreport       Date:  2001-10-08       Impact factor: 1.837

9.  Point mutations at L1280 in Nav1.4 channel D3-S6 modulate binding affinity and stereoselectivity of bupivacaine enantiomers.

Authors:  Carla Nau; Sho-Ya Wang; Ging Kuo Wang
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

10.  Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice.

Authors:  Jennifer M A Laird; Veronika Souslova; John N Wood; Fernando Cervero
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

View more
  10 in total

Review 1.  Subtype-selective targeting of voltage-gated sodium channels.

Authors:  Steve England; Marcel J de Groot
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

Review 2.  Status of peripheral sodium channel blockers for non-addictive pain treatment.

Authors:  Matthew Alsaloum; Grant P Higerd; Philip R Effraim; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2020-10-27       Impact factor: 42.937

3.  Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study.

Authors:  Robert Karoly; Nora Lenkey; Andras O Juhasz; E Sylvester Vizi; Arpad Mike
Journal:  PLoS Comput Biol       Date:  2010-06-17       Impact factor: 4.475

4.  SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation.

Authors:  Eleonora Savio-Galimberti; Peter Weeke; Raafia Muhammad; Marcia Blair; Sami Ansari; Laura Short; Thomas C Atack; Kaylen Kor; Carlos G Vanoye; Morten Salling Olesen; Tao Yang; Alfred L George; Dan M Roden; Dawood Darbar
Journal:  Cardiovasc Res       Date:  2014-07-22       Impact factor: 10.787

5.  A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability.

Authors:  Claire Elizabeth Payne; Adam R Brown; Jonathon W Theile; Alexandre J C Loucif; Aristos J Alexandrou; Mathew D Fuller; John H Mahoney; Brett M Antonio; Aaron C Gerlach; David M Printzenhoff; Rebecca L Prime; Gillian Stockbridge; Anthony J Kirkup; Anthony W Bannon; Steve England; Mark L Chapman; Sharan Bagal; Rosemarie Roeloffs; Uma Anand; Praveen Anand; Peter J Bungay; Mark Kemp; Richard P Butt; Edward B Stevens
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

6.  Mutagenesis of the NaChBac sodium channel discloses a functional role for a conserved S6 asparagine.

Authors:  Andrias O O'Reilly; Anja Lattrell; Andrew J Miles; Alexandra B Klinger; Carla Nau; B A Wallace; Angelika Lampert
Journal:  Eur Biophys J       Date:  2017-08-20       Impact factor: 1.733

7.  Mechanism of sodium channel block by local anesthetics, antiarrhythmics, and anticonvulsants.

Authors:  Denis B Tikhonov; Boris S Zhorov
Journal:  J Gen Physiol       Date:  2017-03-03       Impact factor: 4.086

8.  Conservation and divergence in NaChBac and NaV1.7 pharmacology reveals novel drug interaction mechanisms.

Authors:  Wandi Zhu; Tianbo Li; Jonathan R Silva; Jun Chen
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

9.  Functional modulation of the human voltage-gated sodium channel NaV1.8 by auxiliary β subunits.

Authors:  S T Nevin; N Lawrence; A Nicke; R J Lewis; D J Adams
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

10.  Structural basis for high-voltage activation and subtype-specific inhibition of human Nav1.8.

Authors:  Xiaoshuang Huang; Xueqin Jin; Gaoxingyu Huang; Jian Huang; Tong Wu; Zhangqiang Li; Jiaofeng Chen; Fang Kong; Xiaojing Pan; Nieng Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-19       Impact factor: 12.779

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.